As clinical development grows more complex and globally interconnected, biotech companies are under increasing pressure to build CRO partnerships that deli...
New platform leverages the established Curator® platform methodology to industrialize Lentivirus processes from concept to clinic. Andelyn Bio...
Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) (“Neurizon” or “the Company”), is pleased to announ...
The FDA AMT designation recognizes technologies that demonstrate the potential to significantly improve the quality, reliability, and ...
As biologics, advanced therapies, and specialised injectable medicines continue to reshape the pharmaceutical landscape, the demand for agile and h...
PrognomiQ, a healthcare company focused on harnessing the power of proteomics and multi-omics data to transform the detection and early treatment selecti...
- AOP Health, a global pharmaceutical enterprise group focused on integrated therapies for rare diseases and critical care, announced a strategic pa...
Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stag...
Dark Horse Consulting Group, a leading strategic and operational consulting enterprise in the field of biological therapy (hereinafter referred to as " DHC...
Chance Pharmaceuticals ("Chance" or "Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inha...
Recently, the novel oral BET inhibitor NHWD-870 HCI, independently developed by Zhejiang Wenda Pharmaceutical Technology Co., Ltd., officially recei...
VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positiv...
New company (“NewCo”) co-founded by Nxera with a syndicate of leading healthcare and life sciences-focused investment firms. In return for...
Pierre Fabre Pharmaceuticals, Inc. (PFP), announces it has aligned with FDA on a potential path forward for resubmission of the BLA for tabelecleucel, an...
© 2026 Biopharma Boardroom. All Rights Reserved.
